A new consortium formed by Hospital Clínic de Barcelona - IDIBAPS and Ecopol Tech, aims at develop new drug delivery systems to potentiate and activate the immune system and combat melanoma cancer.
The project had two main objectives, the activation of the specific immune system to tackle melanoma cancer and the nanoencapsulation of hydrophilic immunological regulatory compounds that potentiate the immune system in a general and specific way.
Smart nanocapsules have been successfully designed, which are able to accumulate in tumour areas in mouse models of melanoma cancer by selectively cationization. The drug used in these studies was Resiquimod, a TLR7/8 agonist drug that generates an immune response. The results show a clear decrease of the tumor volume by the administration of Resiquimod-loaded nanocapsules.
A new PCT application has been submitted and approved involving the good results achieved during the project.
*NanoImmuca (Nucli I + D Gen Cat, Collaborative project, 2018-2021) RD17-1-0079 "New multifunctional nanocapsules to potentiate immunologic system to fight against melanoma. Resolution EMC/2755/2017